iOMEDICO AG: all 53 studies
Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerRecruitingNCT07563595
- A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)RecruitingNCT07559799
- Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse GliomaRecruitingNCT07240662
- Research Platform Myelofibrosis and AnemiaRecruitingNCT06976918
- Fruquintinib in Patients With Metastatic Colorectal CancerRecruitingNCT06787105
- Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyRecruitingNCT06743035
- Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational StudyRecruitingNCT06607302
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaRecruitingNCT05326308
- Registry Platform Ovarian and Endometrial CancerRecruitingNCT05129969
- Registry Platform Gastric/Esophageal Cancer (SAPHIR)RecruitingNCT04290806
- Breast Cancer Registry PlatformRecruitingNCT03417115
- Registry Platform Urologic CancerRecruitingNCT03374267
- Myeloma Registry Platform (MYRIAM)RecruitingNCT03308474
- Ripretinib (QINLOCK®) According to Current SmPCCompletedNCT06619275
- Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPCCompletedNCT06181734
- Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05954780
- Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)CompletedNCT05517265
- Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)CompletedNCT05284591
- Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletedNCT05253911
- Registry Platform Colorectal CancerActive, not recruitingNCT04867525
- Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene FusionCompletedNCT04557813
- Liver Cancer Registry PlatformActive, not recruitingNCT04510740
- Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision OncologyCompletedNCT04389541
- Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus ChemotherapyCompletedNCT03911219
- A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerWithdrawnNCT03811418Phase 3
- Patient Preference for Pegfilgrastim (Neulasta®) Application FormsCompletedNCT03619993Not applicable
- Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineCompletedNCT03462251Phase 3
- Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)CompletedNCT03043950
- Patient Reported Outcomes Registry in Patient With Cancer CachexiaCompletedNCT02983500
- Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma PatientsCompletedNCT02970747
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
- Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLCCompletedNCT02799862
- Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple MyelomaCompletedNCT02537808
- Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell CarcinomaCompletedNCT02537743
- Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate CancerCompletedNCT02410044
- Bone Pain Score Validation InitiativeCompletedNCT02293642
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
- Tumor Registry Pancreatic CancerCompletedNCT02089269
- Non-interventional Study With Pomalidomide (Imnovid®)CompletedNCT02075996
- Clinical Tumor Anemia Registry (TAR)CompletedNCT01795690
- Non-interventional Study With Nab-Paclitaxel (Abraxane®)CompletedNCT01689610
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
- Tumour Registry Breast CancerCompletedNCT01351584
- Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)CompletedNCT01266837Phase 4
- Non-interventional Study With Azacitidin (Vidaza®)CompletedNCT01192945
- Tumour Registry Lung Cancer (TLK)CompletedNCT01192919
- Epidemiological EMESIS-RegistryCompletedNCT00911222
- Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and DexamethasoneCompletedNCT00911105
- Tumour Registry Colorectal CancerCompletedNCT00910819
- Tumor Registry of Lymphatic NeoplasiaCompletedNCT00889798
- Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerCompletedNCT00868634Phase 3
- Tumor Registry of Advanced Renal Cell CarcinomaCompletedNCT00610012